 Schizandrine, SCHA, is a powerful antioxidant and anti-inflammatory agent that can be used to treat chronic obstructive pulmonary disease, COPD. It reduces oxidative stress, increases antioxidants, and inhibits the production of reactive oxygen species, ROS, and the activation of the NLRP3-inflammacem, which leads to decreased inflammation and lung damage. Furthermore, SCHA does not cause any significant side effects, making it a promising candidate drug for treating COPD. This article was authored by Jiamin Zeng, Sida Liao, Juliang, and others.